Becton, Dickinson And Co. - 6% PRF CONVERT 01/06/2023 USD 50 - Ser B

Becton, Dickinson And Co. - 6% PRF CONVERT 01/06/2023 USD 50 - Ser B

BDXB - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$13.14B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Becton, Dickinson And Co. - 6% PRF CONVERT 01/06/2023 USD 50 - Ser BBecton, Dickinson And Co. - 6% PRF CONVERT 01/06/2023 USD 50 - Ser B52.51.82%2%0.70.3

Earnings Call Q4 2026

November 5, 2026 - AI Summary

FY2026 results: solid growth + clear earnings/cash improvement - Q4: Revenue $5.3B (+5.6% YoY); Adjusted EPS $4.15 (+27.3% YoY). - Full year: Revenue $19.5B (+3.9%); Adjusted EPS $12.70 (+6.7%). - Earnings quality: Adjusted gross margin 55.1% and operating margin 25%, with margin progress helped by BD Excellence, productivity, and mix (tariffs were a headwind).
Business momentum: growth concentrated in “key platforms,” broad-based execution - Management emphasized double-digit growth across major platforms: Advanced Patient Monitoring (APM), PureWick (UCC), advanced tissue regeneration, biologic drug delivery, and Rowa pharmacy automation. - APM continued ahead of the deal model; PI/UCC investments (notably sales force and commercial actions) are translating into share gains and stronger growth. - Alaris: Strong competitive momentum: +250 bps share for FY, with Q4 also gaining share—however Alaris remains a forecasting headwind in 1H FY2027 due to prior-year comps.
Transformation milestone (New BD): “focused medtech” + BD Excellence as margin/flywheel driver - Call framed FY2026 as completion of the life sciences separation and shift to a pure-play medtech structure. - BD Excellence highlighted as key to resilient supply chain and margin expansion (e.g., ~8% gross productivity in plants and >2,000 Kaizen events). - Investment strategy: targeted commercial/R&D investments expected to be accretive over time; management reiterated the mix of growth platforms and BD Excellence can create a gross margin flywheel.

Exclusive for Stockcircle Pro members

Sign upSign Up

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$13.14 Billion
Enterprise Value$26.79 Billion
Annual dividend$3.00
Dividend yield1.82%
Earnings per Share$4.11
Beta0.56
Outstanding Shares272,944,000

Return

Return on Equity2.25%ROE
Return on Assets2.25%
Return on Invested Capital5.02%

Valuation & Multiples

P/E Ratio52.54P/E Ratio
PEG127.59PEG
Price to Sales0.65Price to Sales
Price to Book Ratio0.39Price to Book Ratio
Enterprise Value to Revenue1.32
Enterprise Value to EBIT10.71
Enterprise Value to Net Income23
Total Debt to Enterprise0.54
Debt to Equity0.28Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Becton, Dickinson And Co.

72,000 employees
CEO: Thomas Polen

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of hea...

Becton, Dickinson And - 6% PRF CONVERT 01/06/2023 USD 50 - Ser B Insider Information FAQ

In the latest 13F quarter on Stockcircle, 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 11 open-market insider sales for Becton, Dickinson And - 6% PRF CONVERT 01/06/2023 USD 50 - Ser B in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.